Previous 10 | Next 10 |
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued fi...
Axonics (NASDAQ: AXNX) specializes in making medical devices to treat bladder and bowel dysfunction. It's the type of therapy that may be embarrassing to some, but the company's financial performance is nothing to be ashamed of. On Monday, the stock hit its 52-week high of $74.4...
Axonics, Inc. (AXNX) Q2 2021 Earnings Conference Call August 5, 2021, 4:30 PM ET Company Participants Neil Bhalodkar - Investor Relations Raymond Cohen - Chief Executive Officer Dan Dearen - President and CFO Conference Call Participants Chris Pasquale - Guggenheim Travis Steed - Barclays Ada...
Axonics Modulation Technologies (NASDAQ:AXNX): Q2 GAAP EPS of -$0.59 misses by $0.09. Revenue of $45.9M (+202.0% Y/Y) beats by $6.08M. As of June 30, 2021, cash and cash equivalents were $231.1 million. Press Release For further details see: Axonics Modulation Technologies EPS misses by...
Total revenue of $45.9 million in 2Q21, including record SNM revenue of $40.2 million Bulkamid ® revenue of $5.7 million in first full quarter since acquisition Fiscal year 2021 revenue guidance increased to a range of $186 million to $188 million Ax...
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the appointment of Esteban López, M.D., MBA, to its board of directors, effective immediately....
BioLife Solutions Announces Changes to Board of Directors Chairman of the Board Raymond W. Cohen Retires After 15 Years of Service CEO Mike Rice Elected Chairman PR Newswire BOTHELL, Wash. , July 14, 2021 /PRNewswire/ -- BioLife Solutions , ...
cagkansayin/iStock via Getty Images Barclays initiated the coverage of Axonics (AXNX) with an outperform recommendation citing the potential of the company to top the current consensus estimates. The price target of $74.00 per share indicates a premium of ~14.5% to the close. “We are b...
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report second quarter 2021 financial results after the market closes on Thursday, August 5, 2021. In conju...
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, has filed a premarket approval (PMA) supplement with the FDA for its newly developed, long-lived, non-rechargeable ...
News, Short Squeeze, Breakout and More Instantly...
Axonics Modulation Technologies Inc. Company Name:
AXNX Stock Symbol:
NASDAQ Market:
Axonics Modulation Technologies Inc. Website:
Axonics, Inc. (NASDAQ: AXNX) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 0.09% on the day to $68.5. Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulat...
Generated record revenue, gross margin and net income in 2Q24 Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results f...
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...